Get started
Author

Caleb Lee

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
2019 · Shanu Modi, Cristina Saura, et al. · New England Journal of Medicine · 2,002
PDF
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study
2020 · Shanu Modi, Haeseong Park, et al. · Journal of Clinical Oncology · 788
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
2017 · Toshihiko Doi, Kohei Shitara, et al. · The Lancet Oncology · 505
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
2019 · Kenji Tamura, Junji Tsurutani, et al. · The Lancet Oncology · 352
Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis
2022 · Guy Jerusalem, Yeon Hee Park, et al. · Cancer Discovery · 107
PDF
Efficacy of Wolbachia-mediated sterility to reduce the incidence of dengue: a synthetic control study in Singapore
2024 · Jue Tao Lim, Somya Bansal, et al. · The Lancet Microbe · 92
PDF
Gravitraps for Management of Dengue Clusters in Singapore
2013 · Caleb Lee, Indra Vythilingam, et al. · American Journal of Tropical Medicine and Hygiene · 75
Abstract PD3-06: Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd ) in HER2 positive metastatic breast cancer
2021 · Shanu Modi, Cristina Saura, et al. · Cancer Research · 62
Effectiveness of Wolbachia-mediated sterility coupled with sterile insect technique to suppress adult Aedes aegypti populations in Singapore: a synthetic control study
2024 · Somya Bansal, Jue Tao Lim, et al. · The Lancet Planetary Health · 60
Gravitrap deployment for adult Aedes aegypti surveillance and its impact on dengue cases
2020 · Janet Ong, Chee-Seng Chong, et al. · PLoS neglected tropical diseases · 56
PDF
Abstract GS3-01: Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03
2022 · Sara Hurvitz, Sung-Bae Kim, et al. · Cancer Research · 55
Exposure‐Response Relationships in Patients With HER2‐Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan
2021 · Ophelia Yin, Hiroji Iwata, et al. · Clinical Pharmacology & Therapeutics · 55
Animal pose estimation: A closer look at the state-of-the-art, existing gaps and opportunities
2022 · Le Jiang, Caleb Lee, et al. · Computer Vision and Image Understanding · 48
Feeding Host Range of Aedes albopictus (Diptera: Culicidae) Demonstrates Its Opportunistic Host-Seeking Behavior in Rural Singapore
2014 · Relus Kek, H. C. Hapuarachchi, et al. · Journal of Medical Entomology · 47
PDF
Using spatial genetics to quantify mosquito dispersal for control programs
2020 · I Filipović, HC Hapuarachchi, et al. · BMC Biology · 43
PDF
Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors
2021 · Shunji Takahashi, Masato Karayama, et al. · Clinical Cancer Research · 37
Inhibition of TFII-I-Dependent Cell Cycle Regulation by p53
2005 · Zana P. Desgranges, Jinwoo Ahn, et al. · Molecular and Cellular Biology · 35
Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2–expressing salivary gland carcinoma: a pooled analysis of two phase I studies
2024 · Shunji Takahashi, Hideaki Bando, et al. · Japanese Journal of Clinical Oncology · 34
Assessing Wolbachia-mediated sterility for dengue control: emulation of a cluster-randomized target trial in Singapore
2024 · Jue Tao Lim, Diyar Mailepessov, et al. · Journal of Travel Medicine · 26
Dengue Suppression by Male Wolbachia-Infected Mosquitoes
2026 · Jue Tao Lim, Chee-Seng Chong, et al. · New England Journal of Medicine · 24
Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review
2022 · Edith A. Perez, Chau Dang, et al. · Breast Cancer Research and Treatment · 20
Abstract GS1-03: [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with HER2-positive metastatic breast cancer previously treated with T-DM1: A phase 2, multicenter, open-label study (DESTINY-Breast01)
2020 · Ian E Krop, Cristina Saura, et al. · Cancer Research · 12
Abstract OT1-07-02: A phase 3, multicenter, randomized, open-label trial of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs investigator’s choice in HER2-low breast cancer (DESTINY-Breast04)
2020 · Shanu Modi, Shoichiro Ohtani, et al. · Cancer Research · 12
Adjacent spillover efficacy of Wolbachia for control of dengue: emulation of a cluster randomised target trial
2025 · Jue Tao Lim, Diyar Mailepessov, et al. · BMC Medicine · 11
Abstract C041: Safety and pharmacokinetic results from a phase 1, multicenter, open-label study of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with advanced HER2-positive breast cancer
2019 · Dwan-Ying Chang, Chia-Chi Lin, et al. · Molecular Cancer Therapeutics · 11
Works count: 68
Citation count: 4,603
H-index: 20
I10-index: 25
Year
Topic
Type